Document Type

Article

Rights

This item is available under a Creative Commons License for non-commercial use only

Disciplines

1.6 BIOLOGICAL SCIENCES

Publication Details

Analyst. 2013 Sep 7;138(17):4769-76

Abstract

The development of new point-of-care coagulation assay devices is necessary due to the increasing number of patients requiring long-term anticoagulation in addition to the desire for appropriate, targeted anticoagulant therapy and a more rapid response to optimization of treatment. However, the majority of point-of-care devices currently available for hemostasis testing rely on clot-based endpoints which are variable and unreliable and are limited to measuring only certain portions of the coagulation pathway. There is a need for the introduction of point-of-care devices that can execute a broader range of tests; for example, the diagnosis of factor-specific diseases, as well as more reliable assays of anticoagulant status, particularly in response to the emergence of new anticoagulant drugs. Here we present a novel fluorescence-based anti-Factor Xa (FXa) microfluidic assay device for monitoring the effect of anticoagulant therapy at the point-of-care. The device is a disposable, laminated polymer microfluidic strip fabricated from a combination of hydrophobic and hydrophilic cyclic polyolefins to allow reagent deposition as well as allowing effective capillary fill. An immobilized FXa fluorogenic substrate was allowed to interact with 10 μl of a plasma/anticoagulant/exogenous FXa mixture within the microfluidic strip in a time-controlled manner. The activity of uncomplexed FXa was measured with excitation at 342 nm and emission at 440 nm. The device was capable of measuring unfractionated and low molecular weight heparins from 0 to 0.8 U/ml within 60 s (CV

DOI

10.1039/c3an00401e

Included in

Biology Commons

Share

COinS